Relator’s $60M+ FCA Claim Affirmed By Seventh Circuit
Minerva Studio | Shutterstock
The relator charged Eli Lilly and Company (Lilly) of submitting false pricing information to the government under the Medicaid Drug Rebate Program (MDRP) by excluding increases in drug prices from its Average Manufacturer Price (AMP) calculations.
🔒 Members Only · Compliance & Enforcement BriefYou’ve reached the member portion of this brief.Members read the full analysis and the source documents in every Brief, six days a week.